Prevalence of thrombophilia in cohort studies and case-control studies
| Reference . | Patients, n (male) . | Age . | Type patients . | FVL mutation . | PTM . | AT deficiency . | PC deficiency . | PS deficiency . | NOS . |
|---|---|---|---|---|---|---|---|---|---|
| Cohort studies | |||||||||
| 8 | 59 (31) | 0-15 y | Cardiac disease | 9/52 (17%) | 3/52 (6%) | 0/52 (0%) | 0/52 (0%) | 0/52 (0%) | 6 |
| 16 | 18 (10) | 0-25 d | Neonates with all VTE | 1/18 (5.6%) | 1/18 (5.6%) | 0/18 (0%) | 1/18 (5.6%)* | 0/18 (0%) | 5 |
| 27 | 30 (12) | 1-20 y | VTE in NS | 4/12 (33%) | 0/12 (0%) | 0/12 (0%) | 0/12 (0%) | 0/12 (0%) | 6 |
| 20 | 52 (39) | 0-1 mo | CVT | 2/41 (5%) | 2/18 (11%) | 6 | |||
| 21 | 39 (17) | 0-18 y | CVT | 4/22 (18%) | 2/18 (11%) | 0/23 (0%) | 0/24 (0%) | 0/23 (0%) | 6 |
| 9 | 92 (44) | 2 d to 20 y | Children with all VTE | 2/42 (4%) | 1/35 (3%) | 1/44 (2%) | 0/49 (0%) | 0/47 (0%) | 5 |
| 28 | 34 (22) | 3-12 y | VTE in NS | 0/18 (0%) | 0/18 (0%) | 1/18 (6%) | 0/18 (0%) | 2/18 (11%) | 5 |
| 10 | 26 (0) | 12-21 y | Contraception-associated VTE | 4/26 (15%) | 3/26 (12%) | 0/26 (0%) | 0/26 (0%) | 1/26 (4%) | 4 |
| 11 | 55 (27) | 0-21 y | Abd VTE | 8/55 (15%) | 5/55 (9%) | 0 (0%) | 5/55 (9%) | 2/5 (4%) | 7 |
| 236 (98) | 0-21 y | LE VTE/PE | 33/236 (14%) | 7/236 (3%) | 1/236 (0.4%) | 2/236 (1%) | 5/236 (2%) | ||
| 12 | 239 (101) | 0-20 y | Inpatients | 13/144 (9%) | 4/125 (3%) | 0/135 (0%) | 0/131 (0%) | 0/131 (0%) | 6 |
| 153 (77) | 0-20 y | Outpatients | 11/105 (11%) | 2/97 (2%) | 1/95 (1%) | 5/99 (5%) | 1/97 (1%) | ||
| Case-control studies | |||||||||
| 23 | Cases 75 (45) | 0-18 y | CVT | 2/7 (29%) | 2/7 (29%) | 8 | |||
| Controls 400 (207) | Newborn | 12/400 (3%) | 13/400 (3%) | ||||||
| 25 | Cases 45 (20) | 0.3-16.4 y | Malignancies and PACs | 2/45 (5%) | 0/45 (0%) | 0/45 (0%) | 0/45 (0%) | 0/45 (0%) | 7 |
| Controls 69 (44) | 0.3-16.2 y | 5/69 (7%) | 3/69 (4%) | 0/69 (0%) | 0/69 (0%) | 0/69 (0%) | |||
| 26 | Cases 25 | 0-18 y | Cardiac disease and CVC | 1/25 (4%) | 0/25 (0%) | 0/25 (0%) | 0/25 (0%) | 1/25 (4%) | 8 |
| Controls 65 | 0-18 y | 3/65 (5%) | 2/65 (3%) | 3/65 (5%) | 2/65 (3%) | 0/65 (0%) | |||
| Reference . | Patients, n (male) . | Age . | Type patients . | FVL mutation . | PTM . | AT deficiency . | PC deficiency . | PS deficiency . | NOS . |
|---|---|---|---|---|---|---|---|---|---|
| Cohort studies | |||||||||
| 8 | 59 (31) | 0-15 y | Cardiac disease | 9/52 (17%) | 3/52 (6%) | 0/52 (0%) | 0/52 (0%) | 0/52 (0%) | 6 |
| 16 | 18 (10) | 0-25 d | Neonates with all VTE | 1/18 (5.6%) | 1/18 (5.6%) | 0/18 (0%) | 1/18 (5.6%)* | 0/18 (0%) | 5 |
| 27 | 30 (12) | 1-20 y | VTE in NS | 4/12 (33%) | 0/12 (0%) | 0/12 (0%) | 0/12 (0%) | 0/12 (0%) | 6 |
| 20 | 52 (39) | 0-1 mo | CVT | 2/41 (5%) | 2/18 (11%) | 6 | |||
| 21 | 39 (17) | 0-18 y | CVT | 4/22 (18%) | 2/18 (11%) | 0/23 (0%) | 0/24 (0%) | 0/23 (0%) | 6 |
| 9 | 92 (44) | 2 d to 20 y | Children with all VTE | 2/42 (4%) | 1/35 (3%) | 1/44 (2%) | 0/49 (0%) | 0/47 (0%) | 5 |
| 28 | 34 (22) | 3-12 y | VTE in NS | 0/18 (0%) | 0/18 (0%) | 1/18 (6%) | 0/18 (0%) | 2/18 (11%) | 5 |
| 10 | 26 (0) | 12-21 y | Contraception-associated VTE | 4/26 (15%) | 3/26 (12%) | 0/26 (0%) | 0/26 (0%) | 1/26 (4%) | 4 |
| 11 | 55 (27) | 0-21 y | Abd VTE | 8/55 (15%) | 5/55 (9%) | 0 (0%) | 5/55 (9%) | 2/5 (4%) | 7 |
| 236 (98) | 0-21 y | LE VTE/PE | 33/236 (14%) | 7/236 (3%) | 1/236 (0.4%) | 2/236 (1%) | 5/236 (2%) | ||
| 12 | 239 (101) | 0-20 y | Inpatients | 13/144 (9%) | 4/125 (3%) | 0/135 (0%) | 0/131 (0%) | 0/131 (0%) | 6 |
| 153 (77) | 0-20 y | Outpatients | 11/105 (11%) | 2/97 (2%) | 1/95 (1%) | 5/99 (5%) | 1/97 (1%) | ||
| Case-control studies | |||||||||
| 23 | Cases 75 (45) | 0-18 y | CVT | 2/7 (29%) | 2/7 (29%) | 8 | |||
| Controls 400 (207) | Newborn | 12/400 (3%) | 13/400 (3%) | ||||||
| 25 | Cases 45 (20) | 0.3-16.4 y | Malignancies and PACs | 2/45 (5%) | 0/45 (0%) | 0/45 (0%) | 0/45 (0%) | 0/45 (0%) | 7 |
| Controls 69 (44) | 0.3-16.2 y | 5/69 (7%) | 3/69 (4%) | 0/69 (0%) | 0/69 (0%) | 0/69 (0%) | |||
| 26 | Cases 25 | 0-18 y | Cardiac disease and CVC | 1/25 (4%) | 0/25 (0%) | 0/25 (0%) | 0/25 (0%) | 1/25 (4%) | 8 |
| Controls 65 | 0-18 y | 3/65 (5%) | 2/65 (3%) | 3/65 (5%) | 2/65 (3%) | 0/65 (0%) | |||
Abd, abdominal; CVC, central venous catheter; CVT, cerebral venous thrombosis; LE, lower extremity; NOS, Newcastle-Ottawa Scale; NS, nephrotic syndrome; PAC, port-a-cath; PE, pulmonary embolism.
Homozygous.